

## NHS ENGLAND – BOARD PAPER

<p><b>Title:</b> Report of the Investment Committee (IC) to the NHS England Board.</p>
<p><b>Lead Director:</b> Moira Gibb, Non-Executive Director and Chair of the IC Paul Baumann, Chief Financial Officer (CFO)</p>
<p><b>Purpose of the paper:</b> To update the Board on the papers circulated by correspondence in September 2017 and the meetings held 4 October 2017 and 3 November 2017.</p>
<p><b>The Board is invited to:</b> Note the content of the report.</p>

## REPORT OF THE INVESTMENT COMMITTEE TO THE BOARD

**Report to the Board from:** Investment Committee  
**Committee Chair:** Moira Gibb, Non-Executive Director  
**Date of Committee meeting:** Papers reviewed by correspondence September 2017 and meetings held 4 October 2017 and 3 November 2017

### Items for the Board's information and assurance

#### Items reviewed by correspondence September 2017

##### Diabetes Prevention Programme (DPP)

The Committee approved by correspondence expenditure on the NHS DPP in 2018/19. This funding will be made available to meet the costs of services and for local CCGs and STPs involved in the programme to support local GP engagement and case finding and referral into the programme in 2018/19.

##### Gloucestershire STP Transformation Programme

The Committee received an update from the Gloucestershire STP Transformation Programme.

#### 4 October 2017 Investment Committee Meeting

##### Mid and South Essex Success Regime

The IC was presented with an overview of the Mid and South Essex Success Regime programme including the progress that has been made through the NHS England assurance process.

The Committee agreed that further work was required in a number of areas in order for the scheme to be presented for approval ahead of consultation, and agreed that the programme would aim for decision at IC on the 3rd November.

##### NHS 111 Vodafone Contract Extension

The IC recommended approval of the NHS 111 Vodafone Contract Extension Full Business Case Addendum and the proposed two year contract extension, subject to satisfactory resolution of a number of conditions. This decision was ratified under Chairman's action following discussion with the Chief Financial Officer and Investment Committee Chair.

##### Oversight Group for Service Change and Reconfiguration (OGSCR)

The Committee noted the pipeline from the OGSCR and summary of the current position on service change across England.

## **3 November 2017 Investment Committee Meeting**

### Congenital Heart Disease

The Committee discussed NHS England's proposals on Congenital Heart Disease, the emerging recommendations, and the readiness of the work for decision making

The Committee noted the decision-making business case (DMBC), the draft consultation report, noted the assurance provided by the Oversight Group for Service Change and Reconfiguration (OGSCR); and approved the work moving forward to decision making by the NHS England Board at its meeting on 30 November 2017. The Committee was assured that the requirements had been satisfied for the Board to take decisions on the proposals for CHD service change in England.

### Mid and South Essex Success Regime

The Committee noted the further assurances provided since discussions held at the OGSCR and the IC following their meetings on 2 October and 4 October respectively, particularly on financial, activity and capacity modelling and the configuration of stroke services.

The Committee agreed that the Mid and South Essex Success Regime programme was ready to progress to consultation, subject to a number of conditions, including that a post-implementation review of the stroke service is performed by the National Clinical Director, and presented back to the Committee.

## **Progress against the Committee's annual work plan**

The IC is working in accordance with the Schedule of Business.

## **Recommendation**

The Board is invited to note the content of the report.